Syntara (ASX:SNT)
ASX announcement history & article coverage
Transparent by design.
Announcments by Syntara (ASX:SNT) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4G and Corporate Governance Statement
Appendix 4E and Annual Report
Syntara reports higher loss on lower revenue; advances clinical pipeline with FDA support and $8.8M capital raise
Investor Update Webinar Presentation
Investor Update Webinar
Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
Syntara advances clinical trials with FDA support and $8M capital raise, extends cash runway to Q3 2027
AZALOX MDS study advances to final Phase 1b cohort
Syntara advances AZALOX Phase 1b trial with dose escalation approved and sites open for recruitment
SNT-4728 Webinar Presentation
Encouraging SNT-4728 Phase 2 iRBD results
Trading Halt
Notification regarding unquoted securities - SNT
Application for quotation of securities - SNT
Proposed issue of securities to the CEO
SNT-9465 scarring trial exceeds 50% enrolment
Change in substantial holding
Section 708A(5)(e) notice
Application for quotation of securities - SNT
Results of Meeting
Application for quotation of securities - SNT
Results of Share Purchase Plan
Syntara completes $0.84M Share Purchase Plan, total raise $8.84M to fund clinical trials and development
